Growing evidence positions GFAP as a biomarker for Alzheimer’s disease with specificity and disease-correlation characteristics comparable to established clinical markers, such as Aβ peptides and phosphorylated tau protein. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.